Important pharmacy news and late-breaking industry information updated daily.
Speaking before the House Select Subcommittee on the Coronavirus Crisis, leading public health physicians told lawmakers on May 13 that the United States must widen its coronavirus testing in order to safely reopen the economy.
A Senate hearing on Tuesday featured warnings from scientists and public health officials that the United States is ill-prepared to reopen and contain the spread of the coronavirus in the coming months. The officials cautioned that a vaccine would very likely not come in time to protect students for the return to school in the fall. Anthony S.
In a letter directed to congressional leaders on May 7, 2020, more than 240 patient advocacy and health care groups urged inclusion of DIR fee reform in the next coronavirus economic stimulus bill. The reforms would reduce patients’ prescription drug costs and help keep pharmacies—many of which serve as a health care hub in underserved communities—open and ready to provide patient care, the groups said. These issues are particularly vital as the nation battles the COVID-19 pandemic.
On May 1, 2020, FDA issued an emergency use authorization (EUA) to Gilead for the investigational antiviral drug remdesivir to treat suspected or laboratory-confirmed COVID-19 in adults and children hospitalized with severe disease. According to the agency, while there is limited information known about remdesivir’s safety and effectiveness to treat people in the hospital with COVID-19, the drug was shown in a clinical trial to shorten the time to recovery in some patients.
Dozens of states are coming out of lockdown even as most have not met minimal criteria for doing so safely; some are reopening even as coronavirus cases rise. The much-feared "second wave" of infection may not wait until fall, many scientists say, and instead may become a storm of wavelets breaking unpredictably across the country.
CDC on Friday warned that the United States could begin seeing outbreaks of measles and other vaccine-preventable diseases because children are failing to get necessary immunizations during the COVID-19 pandemic.
As more and more states approve the use of medical marijuana, hospitals will surely be admitting patients who rely on cannabis for medicinal purposes. Upon admission, institutions will be faced with the decision to allow patients to continue their cannabis as an inpatient or disallow its use for fear of legal repercussions. Therefore, careful planning and the development of policies to guide clinicians are needed as use of medical cannabis becomes more widespread.
FDA on Thursday issued an update on the agency's efforts to combat the companies and individuals who are exploiting or taking advantage of widespread fear during the COVID-19 pandemic and selling unproven medical products.
FDA has approved capmatinib (Tabrecta—Novartis) for the treatment of adults with non-small cell lung cancer (NSCLC) that has spread to other parts of the body. This is the first FDA-approved therapy to treat NSCLC with specific mutations (those that lead to mesenchymal-epithelial transition or MET exon 14 skipping).
In the past 2 days alone, Cohen Children's Medical Center in Long Island, NY, has admitted five critically ill patients—aged 4 years to 12 years—with an unusual sickness that appears to be linked to COVID-19.